Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?

Yıl 2019, Cilt: 9 Sayı: 1, 91 - 93, 29.03.2019

Selami Aykut Temiz , Arzu Ataseven İlkay Ozer Recep Dursun Siddika Findik

https://doi.org/10.33808/marusbed.546841

Cited By: 1

Öz

Objective: Urticarial vasculitis is a chronic clinicopathologic entity characterized by clinically characterized urticarial rash, histopathologically

characterized by leukocytoclastic vasculitis. The pathogenesis is thought to be developed by a type III hypersensitivity reaction similar to

leukocytoclastic vasculitis.

Methods: Antihistamines and/or corticosteroids (systemic/local) may be used in patients with limited normocomplementemic urticarial vasculitis.

In the literature, severe cases treated with dapsone, colchicine, hydroxychloroquine, pentoxifylline, omalizumab, mycophenolate mofetil, rituximab,

cyclosporine, intravenous immunoglobulin, and cyclophosphamide have been reported in the case reports.

Results: In this case, the patient, whose symptoms had not previously responded to treatment with antihistamines, steroids, cyclosporine, and

omalizumab, responded to treatment with methotrexate.

Conclusion: This case report recommends that methotrexate therapy may be a treatment option for cases of resistant urticarial vasculitis.

Anahtar Kelimeler

Urticarial vasculitis, methotrexate, omalizumab

Kaynakça

• [1] Davis MDP, van der Hilst JCH. Mimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases. J Allergy Clin Immunol Pract 2018;6(4):1162-70.
• [2] Sjöwall C, Mandl T, Skattum L, Olsson M, Mohammad AJ. Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). Rheumatology (Oxford) 2018; 57(8):1400- 07.
• [3] Kavala M, Türkoğlu Z, Özlü E. Metotreksat ve dermatolojide klinik kullanımları. Med Med J 2014; 29:104-110.
• [4] Sunderkötter C, De Groot K. Therapie von Vaskulitiden und Vaskulopathien. Der Hautarzt 2008; 59:382.
• [5] Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003; 48:311-40.
• [6] Polat AK, Belli AA, Karakus V, Dere Y. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome. An Bras Dermatol 2017; 92:59-61.
• [7] Black AK. Urticarial vasculitis. Clinics in Dermatology 1999; 17:565-69.
• [8] Katsambas A, Riga P. Purpura and vasculitis: unapproved treatments. Clin Dermatol 2002; 20:626-33.
• [9] Khasnis A, Langford CA. Update on vasculitis. J Allergy Clin Immunol 2009; 123:1226-36.
• [10] 1Shen S, O’Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1-18.
• [11] Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001; 10:1279-89.
• [12] Stack PS. Methotrexate for urticarial vasculitis. Ann Allergy 1994; 72:36-38.
• [13] Perez A, Woods A, Grattan CEH. Methotrexate: a useful steroidsparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162:191-94.
• [14] Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14-21.
• [15] Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology 2014; 10:1519-30.